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DC-SIGN receptorIt is generally believed that during the sexual transmission of HIV-1, the glycan-speciﬁc DC-SIGN receptor
binds the virus and mediates its transfer to CD4+ cells. The lectins grifﬁthsin (GRFT), cyanovirin-N (CV-N)
and scytovirin (SVN) inhibit HIV-1 infection by binding to mannose-rich glycans on gp120. We measured
the ability of these lectins to inhibit both the HIV-1 binding to DC-SIGN and the DC-SIGN-mediated HIV-1
infection of CD4+ cells. While GRFT, CV-N and SVN were moderately inhibitory to DC-SIGN binding, they
potently inhibited DC-SIGN-transfer of HIV-1. The introduction of the 234 glycosylation site abolished HIV-
1 sensitivity to lectin inhibition of binding to DC-SIGN and virus transfer to susceptible cells. However, the
addition of the 295 glycosylation site increased the inhibition of transfer. Our data suggest that GRFT, CV-N
and SVN can block two important stages of the sexual transmission of HIV-1, DC-SIGN binding and transfer,
supporting their further development as microbicides.
© 2011 Elsevier Inc. All rights reserved.Introduction
HIV-1 is mainly transmitted through sexual intercourse that ac-
counts for ~80% of infections around the world (http://www.unaids.
org). In females, transmission begins when viral particles released
into the vaginal tract cross the epithelial cell lining and infect target
cells (Shattock and Moore, 2003). Some of these viruses bind to
intraepithelial or submucosal dendritic cells (DC) via the interaction
of mannose-rich glycans on the HIV-1 envelope with carbohydrate
binding receptors such as DC-SIGN, DC immune receptor (DCIR)
and mannose receptors (Hong et al., 2002; Lambert et al., 2008; Li
et al., 2010; Liu et al., 2004; Piguet and Sattentau, 2004; Pohlmann
et al., 2001). Similarly, in men, the foreskin of the penis contains DC
that express the DC-SIGN receptor and are believed to play a role in
female to male transmission (Fischetti et al., 2009; Hussain and
Lehner, 1995; McCoombe and Short, 2006; Patterson et al., 2002;
Soilleux and Coleman, 2004). The DC-SIGN receptor is also expressed
on rectal mucosa mononuclear cells and may mediate infection, as
these cells have been shown to transfer HIV-1 to CD4+ T cells in
vitro via this receptor (Gurney et al., 2005).
DC are antigen-presenting cells that become activated upon inter-
action with an invading pathogen (Piguet and Sattentau, 2004).nicable Diseases, Johannesburg,
rica. Fax: +27 11 386 6453.
rights reserved.Following this they migrate to the lymph nodes to stimulate naïve
T-helper cells. HIV-1 interaction with the DC-SIGN receptor exploits
this process by enabling the virus to reach the lymph nodes and infect
CD4+ T cells (Banchereau and Steinman, 1998; Lanzavecchia and
Sallusto, 2001). Previous studies suggested that HIV-1 binding to
this receptor can result in its internalization by DC, the so called
Trojan Horse model of trans-infection (Piguet and Sattentau, 2004;
Pohlmann et al., 2001). However, more recent studies dispute this
and propose that surface-bound viral particles mediate DC transfer
of HIV-1 to susceptible cells (Cavrois et al., 2008; Yu et al., 2008).
Nonetheless, in addition to HIV-1 infection in trans (virus transfer
to target cells), it has been shown that DC-SIGN can also promote
the infection in cis (infection of the cell expressing the receptor) of
immature DC and macrophages (Burleigh et al., 2006; Pohlmann
et al., 2001).
Like the DC-SIGN receptor, carbohydrate binding agents or lectins,
bind to mannose-rich glycans found on HIV-1 envelope (Bokesch
et al., 2003; Boyd et al., 1997; Leonard et al., 1990; Mori et al., 2005;
Ziolkowska et al., 2006). Grifﬁthsin (GRFT), cyanovirin-N (CV-N)
and scytovirin (SVN) were isolated from the red algae Grifﬁthsia
sp, the cyanobacteria Nostoc ellipsosporum and Scytonema varium,
respectively. While CV-N is found in both monomeric and dimeric
forms, SVN exists exclusively as a monomer and GRFT as a dimer
(Barrientos et al., 2002; Botos and Wlodawer, 2005; Moulaei et al.,
2007; Ziolkowska and Wlodawer, 2006; Ziolkowska et al., 2006).
Both the native and recombinant forms of these lectins have demon-
strated potent and broad anti-viral activity against laboratory
176 K.B. Alexandre et al. / Virology 423 (2012) 175–186adapted strains and primary isolates of HIV-1 (Alexandre et al., 2010;
Bolmstedt et al., 2001; Esser et al., 1999; O'Keefe et al., 2009; Xiong
et al., 2006). Since these compounds are inhibitors of HIV-1 entry,
they are being actively pursued as potential microbicides for the pre-
vention of HIV-1 transmission (Balzarini and Van Damme, 2007;
Bokesch et al., 2003; O'Keefe et al., 2009).
Previously we showed that GRFT, CV-N and SVN potently inhibit
infection of TZM-bl cells by cell-free viral particles (Alexandre et al.,
2010, 2011). Studies by others have shown that CV-N can inhibit
the DC-SIGN mediated HIV-1 transfer to a cell line expressing the
CD4 receptor (Balzarini et al., 2007). In this study, we investigated
the ability of GRFT and SVN, in addition to CV-N, to inhibit both
HIV-1 binding to the DC-SIGN receptor and the DC-SIGN-mediatedCOT6.15
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Fig. 1. DC-SIGN receptor expression on Raji/DC-SIGN cells. (A) Raji/DC-SIGN and Raji cells w
analyzed by ﬂow cytometry. DC-SIGN expression is shown beneath the bar labeled M1. (B) H
Raji cells at 3 different cell concentrations. The amount of captured virus was measured by
CD209 antibody. The amount of captured virus was measured by p24 ELISA.transfer to target cells. We found that these lectins are efﬁcient inhib-
itors of the DC-SIGN-mediated transfer of HIV-1 to both CD4+ TZM-bl
cells and PBMC. As such, these lectins may be useful in blocking early
events in HIV-1 transmission in mucosal tissues.
Results
GRFT, CV-N and SVN inhibit HIV-1 binding to the DC-SIGN receptor
The lectins GRFT, CV-N and SVN interact with mannose-rich
glycans on the HIV-1 envelope to inhibit the infection of susceptible
cells (Bokesch et al., 2003; Boyd et al., 1997; Mori et al., 2005;
Ziolkowska and Wlodawer, 2006). Since the DC-SIGN receptor alsoQH0692.42
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Fig. 2. Preincubation of HIV-1 with GRFT, CV-N and SVN inhibited binding to the
DC-SIGN receptor. HIV-1 was incubated with GRFT, CV-N and SVN prior to capture on
Raji/DC-SIGN cells. Bound virus was lysed and the amount of captured p24 was measured
by ELISA. Bars represent mean±SD of three different experiments. Untreated controls
are shown in black.
177K.B. Alexandre et al. / Virology 423 (2012) 175–186binds mannose-rich glycans on the viral envelope (Piquet and
Sattenteau, 2004; Pohlmann et al., 2001), we investigated the ability
of GRFT, CV-N and SVN to inhibit HIV-1 binding to the DC-SIGN recep-
tor. For this we used Raji/DC-SIGN cells, a Burkitt's lymphoma cell
line that has been engineered to express the DC-SIGN receptor (Wu
et al., 2004). Using a DC-SIGN speciﬁc antibody, we found that ~55%
of Raji/DC-SIGN cells expressed this receptor as measured by ﬂow
cytometry while control Raji cells did not (Fig. 1A). We ﬁrst evaluated
the ability of HIV-1 to bind to the DC-SIGN receptor by incubating the
virus with Raji/DC-SIGN cells and measuring the amount of cell-
bound p24 after repeated washing. Using the subtype B QH0692.42
and the subtype C COT6.15, we found that both pseudoviruses
bound to Raji/DC-SIGN cells while their binding to control Raji cells
was negligible (Fig. 1B). In addition, the binding to Raji/DC-SIGN
was dependent on the cell concentration used, with 106 cells/mL
showing the highest binding. However, for subsequent experiments
we chose to use 500,000 cells/mL since the differential binding was
in a workable range and minimized the number of cells required. To
discount the possibility that the virus interacted with Raji/DC-SIGN
cells via a mechanism other than binding to the DC-SIGN receptor,
we incubated these cells with mouse anti-human DC-SIGN antibody
prior to the addition of the virus. As shown in Fig. 1C, the antibody
inhibited the binding of two HIV-1 isolates to Raji/DC-SIGN cells con-
ﬁrming the involvement of the DC-SIGN receptor in this interaction.
We then tested GRFT, CV-N and SVN inhibition of HIV-1 binding
to the DC-SIGN receptor by incubating the virus with the lectins
prior to capture with Raji/DC-SIGN cells. Unbound viruses were
removed by repeated washing and the amount of captured virus
was measured by p24 ELISA. Five subtype C (COT6.15, Du151.2,
Du156.12, COT9.6 and CAP63.A9J) and three subtype B (QH0692.42,
PVO.4 and CAAN5342.A2) pseudoviruses were used. Fig. 2 shows
the dose response graphs for two representative viruses that dis-
played lectin-mediated inhibition of binding to DC-SIGN. All three
compounds inhibited in a dose-dependent manner with SVN showing
the weakest effect. Table 1 shows the data for all eight viruses where
the percentage inhibition was calculated based on the amount of p24
antigen at the highest concentration of the lectin relative to the con-
trol. This ranged from 10 to 90% and was highest for CV-N. There was
no correlation between the number and pattern of mannose-rich
glycosylation sites on gp120 and sensitivity to GRFT, CV-N and SVN
(Table 1). For example, COT6.15 (subtype C) and PVO.4 (subtype B)
that both lacked two mannose-rich glycans had very different sensi-
tivities to these lectins. Although there was a trend towards better
inhibition of subtype B compared to subtype C viruses for GRFT
(p=0.072) and CV-N (p=0.054), this was only signiﬁcant for SVN
(p=0.015). The number and position of complex glycans (i.e., not
mannose-rich) also did not affect the sensitivity as expected given
that complex glycans do not bind these lectins (data not shown).
Effects of the 234 and 295 glycosylation sites on lectin inhibition of HIV-1
binding to the DC-SIGN receptor
Previously, while investigating the association between mannose-
rich glycosylation patterns and HIV-1 sensitivity to GRFT, CV-N and
SVN, we observed that glycans at positions 234 and 295 in gp120
increased HIV-1 neutralization sensitivity in TZM-bl cells to all three
lectins (Alexandre et al., 2010). Therefore, we investigated whether
the addition of these sites also affected the inhibition of HIV-1 binding
to the DC-SIGN-receptor. CAAN5342.A2 and CAP63.A9J viruses to-
gether with their 234N and 295N mutants were incubated with the
lectins prior to capture with Raji/DC-SIGN cells. Contrary to what
we expected, the addition of the 234 glycosylation site almost
completely abolished lectin inhibition of CAAN5342.A2 and
CAP63.A9J while the introduction of the 295 glycosylation site had
no effect (Fig. 3). Interestingly, when comparing the amount of p24
antigen captured by Raji/DC-SIGN cells in the absence of lectin(control wells shown as black bars in Fig. 3), the addition of the 234
glycosylation site decreased CAAN5342.A2 binding to the DC-SIGN re-
ceptor by ~50% while it increased CAP63.A9J binding by ~100%. To
further examine this, we also tested COT6.15 which naturally ex-
presses 234N. The deletion of 234N in COT6.15 resulted in a 62% de-
crease in DC-SIGN binding (the wild-type virus bound 2.1 ng/mL
p24 compared to 0.8 ng/mL bound by the COT6-N234Q mutant).
Taken together, our data suggest the glycan at position 234 affects
the binding of HIV-1 to DC-SIGN and also ablates the lectin's ability
to inhibit this interaction.
Inhibition of the DC-SIGN-mediated HIV-1 transfer with GRFT, CV-N and
SVN
Since the DC-SIGN receptor is purported to play a critical role in
transferring the virus to susceptible cells during the sexual transmis-
sion of HIV-1 (Piguet and Sattentau, 2004; Pohlmann et al., 2001), we
tested the ability of GRFT, CV-N and SVN to inhibit DC-SIGN-mediated
transfer of HIV-1 to CD4+ TZM-bl cells. We proceeded by using two
methods to mimic the possibility that when used as a microbicide,
the lectin may interact with the virus prior to or after binding to the
DC-SIGN receptor. In the ﬁrst method, termed the post-DC-SIGN
binding method, the virus was preincubated with Raji/DC-SIGN cells
followed by the addition of the lectin. The lectins were used at con-
centrations previously found to be inhibitory to HIV and non-toxic
to host cells (Alexandre et al., 2010). SVN was the least potent requir-
ing higher concentrations while GRFT, being the most potent, was
Table 1
Inhibition of HIV-1 binding to the DC-SIGN receptor expressed on Raji cells.
HIV-1 envelope
pseudovirus
230 234 241 262 289 295 332 339 386 392 448 c GRFT CV-N SVN
Subtype C
COT9.6 56.4 ± 1.0 69.1 ± 1.8 34.8 ± 18.9
CAP63.A9J 37.9 ± 3.2 68.4 ± 2.9 39.1 ± 11.9
Du156.12 27.7 ± 5.9 34.1 ± 2.0 19.7 ± 0.9
Du151.2 16.5 ± 7.6 46.6 ± 0.4 28.5 ± 6.0
COT6.15 9.8 ± 3.7 46.7 ± 22.5 43.9 ± 3.2
Median 27.7 46.7 34.8
Subtype B
CAAN5342.A2 66.8 ± 0.6 89.7 ± 0.3 50.3 ± 13.0
PVO.4 64.3 ± 23.2 82.3 ± 20.6 57.9 ± 26.4
QH0692.42 40.1 ± 11.1 63.7 ± 2.6 50.8 ± 11.7
Median 64.3 82.3 50.8
a Predicted N-linked mannose-rich glycosylation sites b Percentage inhibition
aMannose-rich glycosylation sites were identiﬁed from the amino acid sequence of each envelope clone (related to HxB2) based on a study using monomeric gp120 (Leonard et al.,
1990). Absent glycans are indicated by black boxes.
bThe percentage inhibition was tested at 345 nM, 450 nM and 1030 nM of GRFT, CV-N and SVN, respectively.
cViruses are ranked according to their sensitivity to GRFT.
178 K.B. Alexandre et al. / Virology 423 (2012) 175–186used at lower concentrations. Virus-bound Raji/DC-SIGN cells were
then co-cultured with TZM-bl cells and the inhibition of transfer
was determined after 48 h. As shown in Table 2, GRFT, CV-N and
SVN inhibited HIV-1 transfer with IC50 in the low nanomolar range.
Similar to our earlier ﬁndings in the TZM-bl neutralization assay
(Alexandre et al., 2010), GRFT was the most potent of the three com-
pounds followed by CV-N and SVN. It is likely that the inhibition of
HIV-1 transfer observed here is related to the neutralization potency
of the lectin. In addition and also in agreement with our previous
study (Alexandre et al., 2010), we observed no correlation between
the number of mannose-rich glycans on gp120 and sensitivity to
GRFT, CV-N and SVN (see Table 1 for glycan patterns). Despite the dif-
ferences in glycosylation patterns (Zhang et al., 2004), HIV-1 subtype
B and C showed similar sensitivity to lectin inhibition of DC-SIGN-
mediated transfer (Table 2).
We also investigated whether GRFT, CV-N and SVN synergized to
inhibit the DC-SIGN mediated HIV-1 transfer. Synergism between
the three lectins was measured by inhibiting the virus transfer with
each lectin alone and in combination and by measuring the combina-
tion index (CI). We used two subtype C, COT9.6 and CAP63.A9J, and
two subtype B, CAAN5342.A2 and QH0692.42, in this experiment. As
shown in Table 3, there was no synergism between GRFT, CV-N and
SVN. On the contrary, the three compounds acted antagonistically
when used in combination, with CI values of >1.1 probably due to
the fact that they share common binding sites on the viral envelope
(Alexandre et al., 2010).
In the second method, termed the pre-DC-SIGN binding method,
the virus was ﬁrst incubated with the lectin before sequentiallyTable 2
Inhibition of HIV-1 transfer to TZM-bl cells via the DC-SIGN receptor.
HIV-1 envelope
pseudovirus
aPost-DC-SIGN binding method
GRFT CV-N SVN
Subtype C
COT9.6 4.8±0.5 31.5±7.3 70.6±1
CAP63.A9J 35.0±5.4 24.0±5.6 441.3±
Du156.12 6.4±0.4 69.2±8.3 161.9±
Du151.2 4.8±0.3 30.8±3.2 82.8±8
COT6.15 5.0±0.1 31.2±0.6 75.9±0
Median 5.0 31.2 82.8
Subtype B
CAAN5342.A2 5.1±0.1 18.8±1.7 115.0±
PVO.4 4.4±0.2 35.7±2.1 82.4±3
QH0692.42 5.3±0.1 36.9±1.4 77.3±5
Median 5.1 35.7 82.4
a,bResults are shown as IC50 (nM) which is the concentration needed to inhibit HIV-1 transadding Raji/DC-SIGN cells and TZM-bl cells. Although, GRFT, CV-N
and SVN inhibited the DC-SIGN-mediated transfer, the sensitivity of
the virus to the three compounds was markedly reduced (Table 2).
Similar to the post-DC-SIGN binding method, GRFT was the most po-
tent and there was no difference between subtypes. Dose–response
curves for two representative viruses in both formats are shown in
Fig. 4. Note that the concentrations used in the pre-DC-SIGN method
were 5–10 fold higher since the lectins are less potent in this format.
We also tested for synergistic interaction between the three lectins
when combined using the pre-DC-SIGN binding method and similar
to the post-DC-SIGN binding method there was antagonism (Table 3).
We then asked the question of whether the combination of both
the post and pre-DC-SIGN binding methods would increase GRFT,
CV-N and SVN inhibition of HIV-1 transfer via the DC-SIGN receptor.
This was investigated by ﬁrst incubating the virus with the lectins
followed by the addition of Raji/DC-SIGN cells. After washing off un-
bound viruses, Raji/DC-SIGN cell bound viruses were again incubated
with the lectins before the addition of TZM-bl cells. For this study we
used COT9.6, CAP63.A9J, CAAN5342.A2 and QH0692.42. Compared to
each method alone, the combination of the pre and post-DC-SGN
binding methods resulted in an increased inhibition of transfer for
COT9.6 and QH0692.42, while the effect was less clear for CAP63.A9J
with CV-N and CAAN5342.A2 with all three lectins (Fig. 5). Lastly,
similar to the post and pre-DC-SIGN binding methods, we observed
antagonism when all three lectins were tested together (Table 3).
Since PBMC are more relevant than TZM-bl cells as HIV-1 targets,
we also tested the inhibition of virus transfer to these primary cells.
To achieve this we used infectious replicating isolates SW7 andbPre-DC-SIGN binding method
GRFT CV-N SVN
4.6 19.4±4.2 154.1±25.6 230.5±9.8
62.9 38.7±5.2 33.7±3.7 590.0±82.4
11.6 28.8±8.3 136.8±73.3 284.0±65.8
.7 11.4±1.0 131.5±46.0 386.5±71.3
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179K.B. Alexandre et al. / Virology 423 (2012) 175–186Du179 (subtype C) and QH0515 (subtype B). Viruses were tested in
both the post and pre-DC-SIGN binding methods and similar to
what we observed in TZM-bl cells, GRFT, CV-N and SVN were inhibi-
tory to HIV-1 transfer with GRFT being the most potent (Figs. 6A
and B). Furthermore, similar to TZM-bl, viruses were more sensitive
to the lectins in the post-DC-SIGN binding method compared to the
pre-DC-SIGN binding method. We also tested the combination of
the pre and post-DC-SIGN binding methods against SW7 and
QH0515 and observed that there was a moderate increase in lectin
inhibition of HIV-1 transfer (Fig. 7). In conclusion, our data show
that GRFT, CV-N and SVN inhibit the DC-SIGN-mediated HIV-1 infec-
tion of PBMC, suggesting that these compounds may be able to inhibit
the virus transfer to primary CD4+ T cells in vivo.
Effects of the 234 and 295 glycosylation sites on lectin inhibition of
DC-SIGN-mediated HIV-1 infection of TZM-bl cells
We next investigated whether the inhibition of the DC-SIGNmedi-
ated HIV-1 transfer was also affected by the 234 and 295 glycosyla-
tion sites. To test this, CAAN5342.A2, CAP63.A9J and their respective
mutants were incubated with Raji/DC-SIGN cells prior to the sequen-
tial addition of the lectin and TZM-bl cells (post-DC-SIGN binding
method). Similar to what we observed for the inhibition of binding,
the addition of the 234 glycosylation site totally abolished the sensi-
tivity to GRFT, CV-N and SVN (Table 4). However, examination of
the virus control (without lectin) showed that the 234N
CAAN5342.A2 virus was 30-fold less efﬁciently transferred (RLU of
4946 compared to 157,591 for the wild-type virus), while
CAP63.A9J-234 N was 3-fold more efﬁciently transferred compared
to the wild-type virus (RLU of 16,498 and 5637). The introduction
of the 295 glycosylation site considerably increased CAP63.A9J and
CAAN5342.A2 sensitivity to the lectins. Similar data were obtained
using the pre-DC-SIGN binding method (Table 4). Note that the
295N mutation had no effect on the efﬁciency of virus transfer.
When put together, these data suggest that the 295 glycan may play
a role in GRFT, CV-N and SVN inhibition of HIV-1 transfer via the
DC-SIGN receptor while the 234 glycan may interfere with this
inhibition.
Discussion
In this study we showed that GRFT, CV-N and SVN inhibit both
HIV-1 binding to the DC-SIGN receptor and the DC-SIGN mediated
transfer of the virus to target cells. However, the inhibition of binding
to DC-SIGN was moderate compared to the inhibition of transfer. In
addition, HIV-1 was more sensitive to the inhibition of transfer
when it bound the lectins after binding to the DC-SIGN receptor.
These effects were modulated by glycan changes at positions 234
and 295 in gp120. Despite documented differences in glycosylation
patterns, subtype B and subtype C viruses overall did not show signif-
icantly different sensitivities to GRFT, CV-N and SVN inhibition of
binding and transfer via DC-SIGN. Given the central role of DC-SIGN
in HIV transmission, further investigation of these compounds as
potential microbicides to prevent the sexual transmission of HIV-1
is warranted.
Lectin inhibition of HIV-1 binding to the DC-SIGN receptor was
partial even at concentrations that were more than 3000-fold higher
than required for neutralization (Alexandre et al., 2010). This is likely
attributed to the promiscuity of the DC-SIGN receptor which can in
addition to mannose-rich also bind complex glycans (Hong et al.,
2007; Liao et al., 2011; Lue et al., 2002). Thus while the lectins block
virus binding via mannose-rich glycans they would have no effect
on virus binding to DC-SIGN via other glycans. It is interesting that
CV-N was the most potent of the 3 lectins in inhibiting the binding
to DC-SIGN, suggesting that CV-N shares more binding sites with
DC-SIGN than GRFT or SVN. These data are in agreement with studies
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Fig. 3. Effects of 234 and 295 glycans on GRFT, CV-N and SVN inhibition of HIV-1 binding to the DC-SIGN receptor. (A) CAAN5342.A2 and (B) CAP63.A9J mutants lacking 234N and 295N
were captured with Raji/DC-SIGN cells in the presence of GRFT, CV-N and SVN. The amount of virus was measured by p24 ELISA and expressed in ng/mL. Bars represent mean±SD of
three different experiments. Untreated controls are shown in black. The highest percentage inhibition obtained with each lectin is show next to the graphs.
180 K.B. Alexandre et al. / Virology 423 (2012) 175–186by Spear who reported that CV-N partially inhibited HIV-1 binding to
DC-SIGN and Banerjee who reported that GRFT incompletely inhib-
ited monomeric gp120 binding to the DC-SIGN receptor, even at
concentrations as high as 10 μM (Banerjee et al., in press; Spear et
al., 2003). A study by Hong showed CV-N did not inhibit HIV-1 JR-
CSF gp120 binding to the DC-SIGN receptor even at 1 mM (Hong et
al., 2002), but given the partial nature of lectin inhibition of binding
to DC-SIGN and the range of sensitivities seen with different viruses
(Table 1), this is perhaps not too surprising. The degree of inhibition
appeared not to be related to the number of mannose-rich or complex
glycans. However, it may be possible that the absence or presence
of single or combinations of mannose-rich glycans is involved in
this differential sensitivity of lectin inhibition of binding to DC-SIGN.
This is suggested by our previous studies showing that the positionof the missing mannose-rich glycans on HIV-1 envelope was more
important than the number in determining sensitivity to GRFT,
CV-N and SVN (Alexandre et al., 2010). While the mannose-rich
glycosylation patterns differ between subtypes B and C (Kwong et
al., 1998; Zhang et al., 2004), this did not have a major impact on
lectin sensitivity. Furthermore, recent data from Go and coworkers
showing that the glycosylation patterns of transmitted founder vi-
ruses from subtypes B and C are similar (Go et al., 2011). Although
this is a single study of one virus from each subtype, it nevertheless
suggests that a GRFT, CV-N or SVN-based microbicide would be
universally effective.
Our data are consistent with that of Balzarini and colleagues who
showed that CV-N inhibited the DC-SIGN-mediated transfer of HIV-1
to CD4+ cells (Balzarini et al., 2007). In addition to CV-N, we show
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Fig. 4. Inhibition of DC-SIGNmediated HIV-1 transfer by post and pre-DC-SIGN binding methods. (A) In the post-DC-SIGN binding method, HIV-1 subtype B QH0692.42 and subtype
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was ﬁrst incubated with GRFT, CV-N and SVN prior to the addition of Raji/DC-SIGN cells and co-culture with TZM-bl cells. The lectins were used at higher concentrations (5 to 10
fold more) in the pre-DC-SIGN binding format. The inhibition of transfer for both methods was determined by measuring the RLU. Bars represent mean±SD of three different ex-
periments. Untreated controls are shown in black.
181K.B. Alexandre et al. / Virology 423 (2012) 175–186here that GRFT and SVN are also inhibitory for HIV-1 transfer with
GRFT being the most potent. The DC-SIGN-mediated HIV-1 transfer
to target cells can be visualized as a two step process: step 1 is the
binding of the virus to the DC-SIGN receptor and step 2 is transfer
to target cells for infection. Thus, the partial sensitivity of HIV-1 to
GRFT, CV-N and SVN inhibition of binding to the DC-SIGN receptor
and its higher sensitivity to the lectin inhibition of the DC-SIGN-
mediated transfer suggests that these compounds are more active
during the second step of the process. This is consistent with the
fact that these three lectins are strong inhibitors of HIV-1 infection
of cells (Alexandre et al., 2010; Bokesch et al., 2003; Boyd et al.,
1997; Mori et al., 2005; O'Keefe et al., 2009). Indeed, the post-DC-
SIGN method measures inhibition of the speciﬁc interaction with
CD4, as opposed to the rather promiscuous interaction with DC-
SIGN via multiple glycans measured in the pre-DC method. Another
possible explanation for the higher potency of the post-DC-SIGN
method is that HIV-1 binding to DC-SIGN could increase the exposure
of mannose-rich glycans on the viral envelope allowing them to
bind more of the inhibitory lectin. However, it is clear that in vivo
the inhibition of transfer by the post-DC-SIGN binding method will
require that the lectins cross the cervico-vaginal mucosa to reach
the sub-epithelium where the virus interacts with DCs and CD4+ T
cells (Lederman et al., 2006; Shattock and Moore, 2003). Since
micro-abrasions of the vaginal mucosa are very common duringsexual intercourse this may offer a way by which these compounds
can breach the mucosal barrier (Norvell et al., 1984). The combination
of the pre and post-DC-SIGN binding methods resulted in increased
sensitivity to GRFT, CV-N and SVN for some of the viruses tested. A
possible explanation for this is that this combination increased the
likelihood of lectins occupying all or most of their binding sites on
the virus, thereby, enhancing their potency. The antagonism observed
with the combination of the three compounds was somewhat
expected since these lectins binding sites overlap on the viral enve-
lope (Alexandre et al., 2010). The ﬁnding that these lectins also inhib-
ited DC-mediated transfer in PBMC in the pre- and post-DC-SIGN
format, suggests that they will also be effective in inhibiting transfer
to CD4+ T cells resident in the cervico-vaginal mucosa (Lederman
et al., 2006; Shattock and Moore, 2003).
The introduction of the 234 glycosylation site abolished GRFT,
CV-N and SVN inhibition of HIV-1 binding to the DC-SIGN receptor
and transfer to target cells. Previously we showed that the 234 glycan
rendered viruses more sensitive to lectin-mediated neutralization
presumably because they bound more lectin. The increased binding
to the DC-SIGN receptor for 2 of 3 viruses in which the 234 glycan
was present suggested that this glycan may be involved in DC-SIGN
binding, similar to complex glycans at positions 158, 276 and 355
and the mannose-rich glycan at position 386 (Hong et al., 2007;
Liao et al., 2011; Lue et al., 2002). The loss of lectin inhibition in the
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182 K.B. Alexandre et al. / Virology 423 (2012) 175–186presence of 234N could, therefore, be the result of increased interac-
tion of HIV-1 with DC-SIGN that supersedes the sensitivity to the lec-
tins. This is suggested by CAP63.A9J and COT6.15 which showed
increased binding to DC-SIGN when 234N was present and a decrease
when this glycan was deleted. The loss of inhibition of binding to DC-
SIGN in the presence of the 234N was also observed for CAAN5342.A2although the decrease in DC-SIGN binding in the presence of this gly-
can was more difﬁcult to understand. Similarly, the 234Nmutants dif-
fered in their ability to be transferred by DC-SIGN. It is important to
note that CAAN5342.A2 differed from CAP63.A9J in that it also lacked
the 339 glycan. It is possible that this extra deglycosylation may be in-
volved in the differences observed between these two viruses. The
importance of the 234 glycosylation site is suggested by the fact
that it is conserved in about 80% of subtype B and C viruses (Zhang
et al., 2004), possibly because it participates in interactions with re-
ceptors such as DC-SIGN. However, we did not observe a correlation
between naturally occurring 234N and binding to DC-SIGN, for ex-
ample PVO.4 which has 234N bound less well to the DC-SIGN recep-
tor compared to CAP63.A9J and CAAN5342.A2 (data not shown),
suggesting this interaction may be contextual.
Similar to 234Nwe also showed previously that the addition of the
295 glycosylation site increased HIV-1 sensitivity to GRFT, CV-N and
SVN (Alexandre et al., 2010). However, we saw no effect of 295N on
DC-SIGN binding while there was increased HIV-1 sensitivity to
GRFT, CV-N and SVN inhibition of the DC-SIGN-mediated transfer in
the presence of 295N. It is, therefore, possible that the effect of the
295 glycosylation site observed here is related to its effect on GRFT,
CV-N and SVN neutralization of HIV-1 only.
The difﬁculties encountered in developing an effective HIV-1 vac-
cine (Johnston and Fauci, 2007; McElrath and Haynes, 2010) and the
fact that the majority of HIV-1 infections are sexually transmitted
(http://www.unaids.org) (Stein, 2003) makes the development of
microbicides that prevent the sexual transmission of the virus crucial.
GRFT, CV-N and SVN block HIV entry into cells and are being actively
pursued as potential HIV-1 microbicides (Bokesch et al., 2003;
O'Keefe et al., 2009; Shattock and Moore, 2003; Xiong et al., 2006).
These compounds have shown little to no toxicity of mammalian
cells in vitro while CV-N tested in a gel formulation as a microbicide
was able to prevent the vaginal and rectal transmission of
SHIV89.6P in macaques (Kouokam et al., 2011; O'Keefe et al., 2009;
Tsai et al., 2003, 2004). In addition, a study conducted in mice showed
that CV-N secreted by engineered vaginal lactobacillus did not induce
a mucosal immune response (Liu et al., 2006). Except for tenofovir
gel, all microbicide candidates that have been tested in human clinical
trials have demonstrated little or no efﬁcacy and some have proven to
be harmful (Abdool Karim et al., 2010; Cutler and Justman, 2008;
Ramjee et al., 2008). The advantage of GRFT, CV-N and SVN is that
they selectively target mannose-rich glycan arrays on HIV-1 that
are not found on mammalian cells (Balzarini, 2005). These lectins
also have the beneﬁt over ARV, such as tenofovir, since they are not
being used for routine HIV-1 treatment. Lastly, GRFT has been
shown to synergize with tenofovir, maraviroc and enfuvirtide against
HIV-1 (Ferir et al., 2011), opening up the possibility of combining
lectins with other compounds in a single formulation. In conclusion,
our data suggest that GRFT, CV-N and SVN could play an important
role in preventing the sexual transmission of HIV-1 by inhibiting
the interaction of the virus with the DC-SIGN receptor in addition to
the CD4 receptor. This supports further investigations on the use of
these lectins for HIV-1 prevention.
Materials and methods
Viruses, cell lines and lectins
SW7 and Du179 are HIV-1 subtype C infectious viruses isolated
from an AIDS and an acutely infected patient, respectively, while
QH0515 is an infectious subtype B from an acutely infected individual
(Cilliers et al., 2003; Li et al., 2005; van Harmelen et al., 2001). The
subtype C envelope clones, COT9.6 and COT6.15 used to generate
pseudoviruses were derived from pediatric isolates (Choge et al.,
2006) while Du151.2, Du156.12 and CAP63.A9J were isolated during
the acute phase of the infection (Gray et al., 2007; Li et al., 2006).
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Fig. 6. DC-SIGN-mediated HIV-1 transfer to PBMC is inhibited by GRFT, CV-N and SVN. HIV-1 subtype C infectious viruses SW7 and Du179 and subtype B QH0515 transfer to PBMC
was inhibited with GRFT, CV-N and SVN using (A) the post and (B) pre-DC-SIGN binding methods. The inhibition of transfer was measured by p24 ELISA. Bars represent mean±SD
of three different experiments. Untreated controls are shown in black. Levels of p24 antigen in the absence of virus or lectins were below detection (not shown).
183K.B. Alexandre et al. / Virology 423 (2012) 175–186HIV-1 subtype B envelopes CAAN5342.A2, QH0692.42 and PVO.4
were from the clade B reference panel (Li et al., 2005). The 234 N
and 295 N mutants of CAAN5342.A2 and CAP63.A9J were generated
by site directed mutagenesis using the QuikChange Site Directed
Mutagenesis Kit (Stratagene, LaJolla, CA) (Alexandre et al., 2010).
The pSG3Δenv plasmid was obtained from Dr. Beatrice Hahn. HIV-1
pseudoviruses were generated by co-transfection of the Env andpSG3Δenv plasmids (Wei et al., 2003) into 293 T cells using the
Fugene transfection reagent (Roche Applied Science, Indianapolis,
IN). Raji cells (Cat No. 9944), a Burkitt's lymphoma cell line (Wu et
al., 2004), and Raji/DC-SIGN cells that express the DC-SIGN receptor
(Cat No. 9945) were provided by the NIH Reference and Reagent Pro-
gram and were cultured in RPMI 1640 containing 10% fetal bovine
serum (FBS). The TZM-bl cell line was obtained from the NIH
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PBMC. SW7 (A) and QH0515 (B) transfer to PBMC was inhibited with GRFT, CV-N
and SVN using the post, pre and combined methods. The values shown are average
of three different experiments.
184 K.B. Alexandre et al. / Virology 423 (2012) 175–186Reference and Reagent Program (Cat No. 8129) while the 293 T cell
line came from the American Type Culture Collection. Both cell lines
were cultured in DMEM containing 10% fetal bovine serum (FBS).
Cell monolayers were disrupted at conﬂuence by treatment with
0.25% trypsin in 1 mM EDTA. Recombinant GRFT, CV-N and SVN
were puriﬁed from E. coli at the National Cancer Institute, MA, USA
(Bokesch et al., 2003; Boyd et al., 1997; Mori et al., 2005).
Expression of the DC-SIGN receptor on Raji/DC-SIGN cells
One million Raji/DC-SIGN or Raji cells were centrifuged at
2000 rpm for 5 min, resuspended in 100 μL of RPMI 1640 containing
10% FBS and stained with 10 μL of phycoerythrin (PE)-labeled
mouse anti-human CD209 (DC-SIGN) (BD, San Jose, U.S.A) for 1 h at
4 °C. Cells were then washed by adding 3 mL of phosphate buffered
saline (PBS) containing 5% fetal bovine serum (FBS) and centrifugedTable 4
Effect of HIV-1 glycosylation on DC-SIGN transfer.
Envelope Genotype Post-DC-SIGN binding methoda IC50 (nM
GRFT CV-N
CAAN5342.A2 bWT 5.1±0.1 18.8±1.7
234N >50 >50
295N 1.5±0.2 7.3±0.1
CAP63.A9J WT 35.0±5.4 24.0±5.6
234N >50 >50
295N 7.9±0.2 9.2±0.1
a The concentration needed to inhibit HIV-1 transfer by 50%.
b Wild type.at 2000 rpm for 5 min. The supernatant was then removed and
300 μL of 1% formaldehyde in PBS (ﬁxer) was added. After 10 min
incubation at 4 °C, cells were analyzed by ﬂow cytometry for the
expression of the DC-SIGN receptor.
DC-SIGN receptor binding assay
HIV-1 pseudoviruses in 20% FBS DMEM were centrifuged for
25 min at 4500 rpm and 4 °C using the 100,000 MWCO PES vivaspin
20 column (Sartorius Stedim biotech, Aubagne, France), to remove
free p24 from the viral samples. This was followed by the determina-
tion of the p24 concentration of the supernatant using the Vironostika
HIV-1 Antigen Microelisa System (Biomerieux, Boseind, the Nether-
lands), according to the manufacturer's instructions. HIV-1 binding
to the DC-SIGN receptor was measured by adding 5 ng of p24 to
1.0×105, 0.5×105 and 0.25×105 Raji/DC-SIGN cells in 100 μL of
RPMI 1640 containing 10% FBS, in a U bottom 96 well plate. The
virus and the cells were incubated at 37 °C for 2 h and then washed
three times with RPMI 1640 by centrifuging at 2000 rpm for 5 min.
Cell bound viral particles were then lysed with 150 μL of 0.5%
Triton-X 100 and the amount of captured p24 was measured by
ELISA.
The interaction between HIV-1 and the DC-SIGN receptor on
Raji/DC-SIGN cells was conﬁrmed by incubating 105 cells with a se-
rial dilution of mouse anti-human CD209 antibody (BD Biosciences,
San Jose, California) for 1 h. The cells were then washed three times
with RPMI 1640, by centrifuging at 2000 rpm for 5 min, and incubat-
ed with 5 ng of p24 for 2 h at 37 °C. After the incubation they were
again washed three times and bound viruses were lysed with
150 μL of 1% empigen. The amount of captured p24 was measured
by ELISA.
GRFT, CV-N and SVN inhibition of HIV-1 binding to the DC-SIGN
receptor was measured by preparing a ﬁve-fold dilution series of
these lectins in 100 μL of RPMI 1640 containing 10% FBS, in a U
bottom 96-well plate. This was followed by the addition of 50 μL
of 5 ng/mL of HIV-1 pseudovirus-containing supernatant and 1 h
incubation at 37 °C. Subsequently 100 μL of 0.5×105 Raji/DC-SIGN
cells/mL was added and incubated at 37 °C for 2 h. The plate was
then washed three times with RPMI 1640 by centrifuging at
2000 rpm for 5 min and virus bound to Raji/DC-SIGN cells was lysed
with 150 μL of 0.5% Triton-X 100. The amount of captured p24 was
measured by ELISA in the presence and absence of lectins.
DC-SIGN-mediated transfer of HIV-1 infection
The DC-SIGN-mediated HIV-1 transfer to TZM-bl cells was carried
out by incubating 7.5×104 Raji/DC-SIGN cells/well with HIV-1 pseu-
dovirus in a U bottom 96 well plate at 37 °C for 1 h. Cells were then
washed three times with RPMI 1640 by centrifuging at 2000 rpm for
5 min to remove unbound viruses and resuspended in 150 μL of 10%
FBS DMEM (growth medium). This was followed by the transfer of
100 μL to the corresponding wells of a ﬂat bottom plate. Subsequent-
ly, 3×104 TZM-bl cells/100 μL of growth medium/well were added) Pre-DC-SIGN binding method IC50 (nM)
SVN GRFT CV-N SVN
115.0±2.4 7.1±0.4 24.2±2.1 153.0±9.7
>500 >50 >50 >500
66.8±3.0 3.5±0.3 13.4±0.3 140.6±9.0
411.3±62.9 38.7±5.2 33.7±3.7 590.0±82.4
>500 >50 >50 >500
228.3±3.0 11.5±0.7 18.2±1.0 357.1±47.3
185K.B. Alexandre et al. / Virology 423 (2012) 175–186to the plate that was then placed at 37 °C for 48 h. The Bright Glo™
Reagent (Promega, Madison, WI) was used to measure infection
after 48 h of culture, according to the manufacturer's instructions.
Luminescence was measured in a Wallac 1420 Victor Multilabel
Counter (Perkin-Elmer, Norwalk, CT).
GRFT, CV-N and SVN inhibition of DC-SIGN-mediated HIV-1 infec-
tion was measured by using two methods. In the ﬁrst method (post-
DC-SIGN binding method) Raji/DC-SIGN cells were incubated with
the virus for an hour and after the removal of unbound viruses a
ﬁve-fold dilution series of GRFT, CV-N and SVN in 150 μL of growth
medium was added. This was followed by a 1 hour incubation at
37 °C and transfer of 100 μL from each well to the corresponding
well of a ﬂat bottom 96 well plate. Subsequently, 3×104 TZM-bl
cells/100 μL of growth medium/well were added to the plate that
was then placed at 37 °C for 48 h; HIV-1 infection was measured as
described above. Raji cells co-cultured with TZM-bl cells, in the
absence of the virus, were used here as background controls. In the
second method (the pre-DC-SIGN binding method), HIV-1 pseudo-
virus was ﬁrst incubated for 1 h at 37 °C with serially diluted GRFT,
CV-N and SVN in 150 μL of growth medium before the subsequent
addition of Raji/DC-SIGN cells and TZM-bl cells. When the pre and
post-DC-SIGN binding methods were combined, the virus was incu-
bated with the lectins for an hour before addition of Raji/DC-SIGN
cells for 2 h. This was followed by washing and a second incubation
with the lectins. The cells were then co-cultured with TZM-bl cells
for 48 h. To determine synergism between GRFT, CV-N and SVN the
inhibition of transfer was tested for each lectin alone and in combina-
tion. Synergism, additive effect or antagonism was determined by
calculating the combination index (CI) using IC50 (Chou and Talalay,
1984; Xu et al., 2001). A CI of 0.3 to 0.7 was deemed indicative of syn-
ergism, 0.7 to 0.85 of moderate synergism, 0.85 to 0.9 of slight syner-
gism, 0.9 to 1.1 of an additive effect and >1.1 of antagonism as
previously deﬁned (Chou and Talalay, 1984; Zwick et al., 2001).
For the inhibition of HIV-1 transfer to phytohemagglutin (PHA) /
interleukin-2 stimulated peripheral blood mononuclear cells (PBMC),
the post and pre-DC-SIGN binding method described above were used
with some modiﬁcations. With the post-DC-SGN binding method,
Raji/DC-SIGN were ﬁrst allowed to bind to infectious HIV-1 subtype C
primary isolates, before incubation with serially diluted GRFT, CV-N
and SVN. Subsequently virus-bound Raji/DC-SIGN cells were co-
cultured with PHA-activated PBMC (5×105 cells/well). The cells were
cultured in RPMI 1640 containing 20% FBS and interleukin-2. PBMC
cultured with Raji cells in the absence of the virus and lectins were
used as negative controls. After 24 h Raji/DC-SIGN cells and PBMC
were washed three times by centrifuging at 1200 rpm for 5 min. All
the washing steps were performed with 20% FBS RPMI 1640. Thereon
the culture supernatant was collected twice daily and replaced with
an equal amount of fresh growth medium. For each harvest the p24
antigen concentration in the virus control wells was measured. The
inhibitory activity of the lectins was measured at the time-point that
corresponded to the early part of the linear growth period of the virus
control (Zhou and Monteﬁori, 1997). The IC80 were calculated by plot-
ting the lectin concentration vs. the percentage inhibition in a linear
regression using GraphPad Prism 4.0. With the pre-DC-SIGN binding
method, HIV-1 was ﬁrst incubated for 1 h at 37 °C with serially diluted
GRFT, CV-N and SVN before the subsequent addition of Raji/DC-SIGN
cells and PBMC. In the combined method the virus was incubated with
the lectins prior and after incubation with Raji/DC-SIGN. Virus bound
Raji/DC-SIGN cells were then co-cultured with PBMC and HIV-1 in-
fection was determined as explained above.
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